Our specific screen of GPR161 in our cohort of 27 PTCH1/SUFU pathogenic variant-negative patients with Gorlin syndrome found no pathogenic or likely pathogenic variants. This evidence concerns the gene GPR161 and nevoid basal cell carcinoma syndrome.